These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11126145)

  • 1. The emerging role of HDL cholesterol. Is it time to focus more energy on raising high-density lipoprotein levels?
    Safeer RS; Cornell MO
    Postgrad Med; 2000 Dec; 108(7):87-90, 93-8. PubMed ID: 11126145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of 14-year changes in the total cholesterol to high-density lipoprotein cholesterol ratio in men.
    Scranton R; Sesso HD; Stampfer MJ; Levenson JW; Buring JE; Gaziano JM
    Am Heart J; 2004 Jun; 147(6):1033-8. PubMed ID: 15199352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Niacin as a component of combination therapy for dyslipidemia.
    Miller M
    Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of diabetic dyslipidemia.
    Garg A
    Am J Cardiol; 1998 Feb; 81(4A):47B-51B. PubMed ID: 9526814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M; Sazonov V; Gutkin SW; Hokanson JE
    J Cardiovasc Pharmacol; 2008 Apr; 51(4):331-51. PubMed ID: 18427276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does hypertriglyceridemia increase risk for CAD? Growing evidence suggests it plays a role.
    Coughlan BJ; Sorrentino MJ
    Postgrad Med; 2000 Dec; 108(7):77-84. PubMed ID: 11126144
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for treatment.
    Gotto AM
    Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The therapeutic role of niacin in dyslipidemia management.
    Boden WE; Sidhu MS; Toth PP
    J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk.
    Furberg AS; Veierød MB; Wilsgaard T; Bernstein L; Thune I
    J Natl Cancer Inst; 2004 Aug; 96(15):1152-60. PubMed ID: 15292387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niacin after coronary bypass grafting and for coronary disease prevention.
    Parsons WB
    Circulation; 2001 Jul; 104(2):E7. PubMed ID: 11447097
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol.
    Bowen PH; Guyton JR
    Curr Atheroscler Rep; 2000 Jan; 2(1):58-63. PubMed ID: 11122725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics and coronary risk factors of patients with low concentrations of serum low-density lipoprotein cholesterol and total cholesterol.
    Lien WP; Lai LP; Hwang JJ; Lin JL; Chen JJ; Tsai KS
    J Formos Med Assoc; 1998 Nov; 97(11):745-9. PubMed ID: 9872030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
    Jacobson TA
    Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations of HDL, HDL(2), and HDL(3) cholesterol and apolipoproteins A-I and B with lifestyle factors in healthy women and men: the Stanford Five City Project.
    Gardner CD; Tribble DL; Young DR; Ahn D; Fortmann SP
    Prev Med; 2000 Oct; 31(4):346-56. PubMed ID: 11006059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of coronary heart disease. Part I. Primary prevention.
    Liebson PR; Amsterdam EA
    Dis Mon; 1999 Dec; 45(12):497-571. PubMed ID: 10711300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Niacin--an additive therapeutic approach for optimizing lipid profile].
    Wieneke H; Schmermund A; Erbel R
    Med Klin (Munich); 2005 Apr; 100(4):186-92. PubMed ID: 15834527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low high-density lipoprotein cholesterol and other coronary heart disease risk factors in patients with total cholesterol levels greater than 5.17 mmol/L (200 mg/dL) in family practice. A report from CEN.
    J Am Board Fam Pract; 1991; 4(5):285-97. PubMed ID: 1746296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.